Please upgrade your browser.
An enzyme called FBP1 -- essential for regulating metabolism -- binds to a transcription factor in the nucleus of certain kidney cells and restrains energy production in the cell body, researchers report.
Immunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials.
Technique using magnetic nanomaterials offers promise for diagnosis, gene therapy
“To see the impact that we make on the families around the area, with kidney cancer families, is always very rewarding,” tight end Adam Breneman said.
Many well-known pharmacy benefit managers and insurance companies, including Express Scripts, Catamaran, Optum, United HealthCare, and BCBS of various states, have made major changes to their coverage of prescribed compounded medicines.
Prof. Dr. Marniza Saad, Associate Professor and Consultant Oncologist at University Malaya Medical Centre
Dr. Robert Figlin describes a clinical trial for patients with advanced disease.
Recent report of MET inhibition strengthened the role of c–Met inhibition across pRCC.
Brian I. Rini, MD, presents a case study focused on the treatment of a 64 year-old male who presented with recurrent lung nodules 9 years after a left radical nephrectomy for a clear-cell renal cell carcinoma (RCC).
Patients with high cholesterol had a 43 percent lower risk of dying.
|Powered by NeonCRM|